BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for February: Feb 1: Discovery Labs ( DSCO): Surfaxin regulatory update conference call. Earnings: Biogen Idec ( BIIB), Pfizer ( PFE). Feb. 2 Earnings: Sangamo BioSciences ( SGMO), Viropharma ( VPHM). Feb 3: Alimera Sciences ( ALIM): 36-month results from phase III study of Iluvien in diabetic macular edema. Earnings: Alkermes ( ALKS), GlaxoSmithKline ( GSK), Avanir Pharmaceuticals ( AVNR), Merck ( MRK), Vertex Pharmaceuticals ( VRTX), Feb. 8: Adeona Pharmaceuticals ( AEN) investor/analyst day. Earnings: Seattle Genetics ( SGEN), Rigel Pharmaceuticals ( RIGL), Teva ( TEVA), Feb. 9: Earnings: Sanofi-Aventis ( SNY) Feb. 10: Earnings: Alexion Pharmaceuticals ( ALXN), Cephalon ( CEPH), Incyte Pharmaceuticals ( INCY), MannKind ( MNKD), Momenta Pharmaceuticals ( NNTA). Feb 14-15: BIO CEO & Investor Conference, New York City. Feb 15: Expiration of Sanofi-Aventis' $69-a-share tender offer for Genzyme ( GENZ). Feb. 16: Earnings: Genzyme Feb. 17: Exelixis ( EXEL): Presentation of updated cabozantinib (XL184) data in prostate cancer at ASCO GU symposium Earnings: Biomarin Pharmaceuticals ( BMRN), Acorda Therapeutics ( ACOR) Feb. 22: Earnings: Questcor Pharmaceuticals ( QCOR) Feb 25: Pfizer and Protalix Therapeutics ( PLX): FDA approval decision date for Uplyso in Gaucher's disease. Other potential February events Idenix Pharmaceuticals ( IDIX): FDA decision on lifting clinical hold on hepatitis C drugs IDX184 and IDX320. Amylin Pharmaceuticals ( AMLN), Alkermes, Eli Lilly ( LLY): Start of a Bydureon Qt study. Source: Company reports, BioMedTracker.com --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.